About STipe Therapeutics
STipe Therapeutics is a Healthcare company based in Aarhus (Denmark) founded in 2018. Cancer therapeutics targeting STING pathway interactions are developed. STipe Therapeutics has raised $23.41 million across 1 funding round from investors including Arix Bioscience, Novo Holdings and Wellington Partners Venture Capital. The company has 1 employees. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Innate Immune System. Its legal entity is STIPE Therapeutics ApS.
Company details
STipe Therapeutics was founded in 2018 in Aarhus, Denmark, within the biotechnology sector. Therapeutics for cancer treatment are developed by the company, focusing on intracellular protein-protein interactions in the STING pathway. This approach is designed to enhance the innate immune systems detection of tumor-DNA, thereby aiding in the prevention of tumor cell growth. Operations center on drug development for oncology applications.
- Headquarters Aarhus, Denmark
- Employees 1
- SectorsHealthcare
- Website stipetherapeutics.com
- Social LinkedIn
- Legal Name Stipe Therapeutics Aps
- Net Profit-$1.17 M (USD)-51as on Dec 31, 2022
- EBITDA-$1.28 M (USD)-45as on Dec 31, 2022
- Total Equity Funding$23.41M (USD)
in 1 rounds
- Latest Funding Round$23.41M (USD), Series A
Sep 2019
- InvestorsArix Bioscience
& 3 more
- Employee Count1
Funding Insights of STipe Therapeutics
STipe Therapeutics has successfully raised a total of $23.41M through 1 strategic funding round. The most recent funding activity was a Series A round of $23.41 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $23.41M
- Total Rounds 1
- Last Round Series A — $23.41M
- First Round $23.41M
(Sep 2019)
- Investors Count 4
All 1 funding rounds of STipe Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $23.41M | Series A | – | Arix Bioscience, Novo Holdings |
4 investors in total: 4 institutional.
Investors in STipe Therapeutics
STipe Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Arix Bioscience, Novo Holdings and Wellington Partners Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in biotech startups are made by Arix Bioscience. | 2016 | arixbioscience.com | London, United Kingdom | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Investments are made in early-stage healthcare startups. | wellington-partners.com | Munich, Germany | ||
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark |
Investor details for STipe Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of STipe Therapeutics
3 people are tracked at STipe Therapeutics (2 in leadership, 1 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Claus Olesen | Co-Founder/CEO | Leadership |
Richard Bethell | Chief Development Officer | Leadership |
Justin Joseph | Senior Scientist | Team |
Complete people profiles for STipe Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of STipe Therapeutics
2 dated milestones of STipe Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded STipe Therapeutics is founded.
- Funding First funding round of $23.4M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stipe Therapeutics
Complete news archive for STipe Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about STipe Therapeutics
STipe Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
STipe Therapeutics is headquartered in Aarhus, Denmark.
STipe Therapeutics is a funded company, having raised a total of $23.41M across 1 funding round to date. The company's 1st funding round was a Series A of $23.41M, raised on Sep 2019.
STipe Therapeutics has 1 employees.
STipe Therapeutics was founded in 2018 in Aarhus, Denmark, within the biotechnology sector. Therapeutics for cancer treatment are developed by the company, focusing on intracellular protein-protein interactions in the STING pathway. This approach is designed to enhance the innate immune systems detection of tumor-DNA, thereby aiding in the prevention of tumor cell growth. Operations center on drug development for oncology applications.
STipe Therapeutics has 4 investors. Key investors include Arix Bioscience, Novo Holdings, Wellington Partners Venture Capital, and Sunstone.
STipe Therapeutics operates through Stipe Therapeutics Aps.